| 2025-04-01 | -1.42 % |
|
| 2025-03-24 | +2.06 % |
|
| 2025-03-20 | +2.36 % |
|
| 2025-03-18 | -0.91 % |
|
| 2025-03-14 | +3.23 % |
|
| 2025-03-13 | -3.22 % |
|
| 2025-03-12 | +0.71 % |
|
| 2025-03-11 | -0.65 % |
|
| 2025-03-10 | -9.15 % |
|
| 2025-03-07 | -2.1 % |
|
| 2025-03-06 | -2.99 % |
|
| 2025-02-26 | +1.8 % |
|
| 2025-02-21 | -0.63 % |
|
| 2025-02-18 | +1.64 % |
|
| 2025-02-14 | +5.92 % |
|
| 2025-02-13 | +0.26 % |
|
| 2025-02-11 | -2.14 % |
|
| 2025-02-10 | +0.22 % |
|
| 2025-02-06 | -0.52 % |
|
| 2025-02-05 | +1.51 % |
|
| 2025-02-04 | +0.47 % |
|
| 2025-02-03 | +0.25 % |
|
| 2025-01-28 | +0.94 % |
|
| 2025-01-24 | +1.2 % |
|
| 2025-01-17 | -0.54 % |
|
| 2025-01-15 | +1.55 % |
|
| 2024-12-27 | -0.41 % |
|
| 2024-12-24 | +0.88 % |
|
| 2024-12-20 | +5.57 % |
|
| 2024-12-19 | +0.74 % |
|
| 2024-12-17 | +1.82 % |
|
| 2024-12-10 | +1.28 % |
|
| 2024-12-09 | +0.89 % |
|
| 2024-12-02 | +1.69 % |
|
| 2024-11-26 | +0.14 % |
|
| 2024-11-25 | +6.87 % |
|
| 2024-11-22 | -2.19 % |
|
| 2024-11-19 | -1.82 % |
|
| 2024-11-18 | +0.51 % |
|
| 2024-11-12 | +5.73 % |
|
| 2024-11-08 | +1.52 % |
|
| 2024-11-06 | -0.57 % |
|
| 2024-11-01 | -0.18 % |
|
| 2024-10-31 | -1.84 % |
|
| 2024-10-30 | -0.61 % |
|
| 2024-10-29 | +0.19 % |
- DexCom (DXCM) stock rose 0.19% as recent analyst reports indicate a mix of price target reductions and upgrades, reflecting continued positive sentiment towards the company's growth potential in the continuous glucose monitoring market.
The stock's increase can be attributed to the presence of multiple buy ratings from analysts despite some downward adjustments in price targets, suggesting confidence in the company's long-term prospects.
- DexCom (DXCM) stock increased by 0.19% as analysts issued mixed ratings, with some upgrading the stock while others lowered earnings forecasts, reflecting a generally positive outlook despite recent estimate adjustments.
The reason for DexCom's stock increase could be attributed to analysts maintaining a "buy" or "outperform" ratings and potential continued institutional investment interest, indicating confidence in the company's future performance.
- DexCom (DXCM) stock increased by 0.19% following Forsta AP Fonden's disclosure that it raised its position in the company by 16.6% in the third quarter, indicating positive investor sentiment and confidence in the stock.
- DexCom (DXCM) stock rose 0.19% after Wells Fargo & Company increased its price target for the company from $80.00 to $90.00, signaling strong investor confidence in the medical device firm.
- DexCom (DXCM) stock rose by 0.19% despite a price target reduction from Lehink Partners and mixed ratings from various analysts, indicating some investor confidence amid the fluctuations. The stock may have gone up due to overall positive sentiments from analysts, where the majority still maintain a buy rating and highlight the potential for growth despite recent target cuts.
- The article discusses a lawsuit against Acadia Healthcare Company, which alleges financial misrepresentations related to insurance fraud, impacting investor confidence and causing a drop in Acadia's stock price, while also highlighting a slight increase of 0.19% in Dexcom (DXCM) stock, possibly as a market reaction to broader movements in the healthcare sector or investor sentiment.
Dexcom's stock may have gone up due to its perceived stability amidst the negative news regarding Acadia Healthcare, attracting investors seeking safer options.
- DexCom, Inc. (DXCM) stock rose by 0.19% due to increased institutional investments, with significant share acquisitions from multiple investors like Forsta AP Fonden and Assenagon Asset Management, indicating a strong market interest in the company.
|
| 2024-10-28 | -1.82 % |
|
| 2024-10-25 | -1.88 % |
|
| 2024-10-24 | +3.27 % |
- Dexcom (DXCM) stock rose by 3.27% last night, likely due to positive market sentiment and advancements in its product offerings, although specific reasons for the increase were not detailed in the article.
- The article discusses various sports news, including updates on rugby squads, Gaelic games, and soccer matches, but it does not provide specific information on why Dexcom (DXCM) stock experienced a 3.27% increase.
The rise in Dexcom stock could be attributed to positive market sentiment, favorable news related to the company's performance or advancements, or broader trends in the healthcare sector. However, the article does not detail any specific reasons for this increase.
- The article discusses a positive turn in U.S. and global markets, led by a significant surge in Tesla's stock, which impacted overall investor sentiment and contributed to Dexcom (DXCM) stock rising by 3.27%.
Dexcom's stock likely went up due to the positive market sentiment stemming from strong corporate earnings reports, particularly from major companies like Tesla, and decreasing Treasury yields, which can lead to increased investor confidence in growth stocks.
- DexCom (DXCM) stock rose by 3.27% following Taylor Frigon Capital Management LLC's disclosure of a 51.6% increase in its stake in the company, indicating strong institutional confidence in DexCom.
- Dexcom (DXCM) stock rose 3.27% likely due to positive market sentiment around its performance amidst a broader mixed trading environment in equity markets, where certain tech and financial stocks were showing resilience and gains.
|
| 2024-10-23 | -0.82 % |
|
| 2024-10-22 | +0.65 % |
|
| 2024-10-21 | +0.32 % |
|
| 2024-10-18 | +4.07 % |
- DexCom (DXCM) stock rose by 4.07% following recent disclosures regarding institutional trading activity, particularly CX Institutional significantly reducing its holdings, alongside positive earnings results that topped expectations and an overall strong market interest in diabetes management solutions.
- DexCom, Inc. (DXCM) stock rose 4.07% after Swedbank AB increased its holdings in the company by 15.2%, acquiring an additional 28,289 shares in the third quarter, signaling growing investor confidence in the company's performance.
- The article discusses a class action lawsuit against DexCom, Inc. for allegedly misleading investors about its financial performance, yet the stock rose by 4.07% likely due to speculative investor optimism or broader market trends despite the legal issues faced by the company.
- DexCom (NASDAQ: DXCM) stock experienced a 4.07% increase due to significant institutional investment, as Exchange Traded Concepts LLC boosted its holdings by 39.5% and other firms also increased their stakes, reflecting positive investor sentiment and confidence in the company's growth prospects amidst favorable quarterly earnings reports and numerous buy ratings from analysts.
|
| 2024-10-17 | -0.5 % |
|
| 2024-10-16 | +4.17 % |
|
| 2024-10-15 | -3.01 % |
|
| 2024-10-14 | -0.04 % |
|
| 2024-10-11 | -0.5 % |
|
| 2024-10-10 | -0.09 % |
|
| 2024-10-09 | +0.27 % |
|
| 2024-10-08 | +1.18 % |
|
| 2024-10-07 | +0.75 % |
|
| 2024-10-03 | -2.12 % |
|
